Navigation Links
Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology

BURLINGTON, Mass., Dec. 13, 2011 /PRNewswire/ -- Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that an oral presentation on CNDO-109 was given at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held at the San Diego Convention Center in California.  CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.

Dr. Panagiotis Kottaridis of the Department of Haematology, Royal Free Hampstead NHS Trust and University College London Medical School, UK reported the final results of the Phase 1 clinical trial of CNDO-109 in AML (abstract #946).  The results demonstrated that AML patients experienced a longer complete remission (CR) after receiving CNDO-109 activated NK cells than their previous CR.

The analysis was based on eight AML patients of whom five were in a subsequent CR, one was in their first CR, one was in partial relapse (PR) and one was in relapsing disease.  As conditioning, patients received fludarabine 25mg/m2/day for three days plus a single fraction (2Gy) total body irradiation (TBI) on day four.  24 hours after the completion of TBI, patients received 1 million activated haploidentical related donor CNDO-109 tumor primed NK cells as a single i.v. infusion. 

Three of the patients in a subsequent CR demonstrated a longer CR than their previous one, and the patient in PR reverted to CR.  No comparison was available for the patient in their first CR, and the patient in relapsing disease was not evaluable.

No toxicity related to the infusion was observed. Seven patients experienced bone marrow suppression with a median time of 55 days (19-101) for neutrophil recovery. Two patients who previously had an allogeneic transplant were salvaged with a CD34+ top up stem cell transfusion from their original donors. All patients experienced neutropenic fevers requiring antibiotic support.

Dr. Panagiotis Kottaridis commented, "In my experience it is unusual for any patient with AML to have subsequent CRs longer than their previous CRs. In this study, the majority of patients experienced this after treatment with CNDO-109 activated NK cells.  This finding demonstrates that CNDO-109 may have a significant role in treating AML patients and supports further development of the product."

Coronado Biosciences expects to file an IND on CNDO-109 with the US FDA in the first quarter of 2012 and initiate a Phase I/II dose escalation trial in AML patients shortly thereafter. 

CNDO-109 was discovered by Dr. Mark Lowdell, Director of Cellular Therapy & Biobanking at Royal Free Hampstead NHS Trust and Assistant Professor and Senior Lecturer in Hematology at University College London.

About CNDO-109

CNDO-109 is a novel anti-cancer drug that primes natural killer (NK) cells without the need for cytokine (IL-2) treatment and shows significant potential for the treatment of hematological and solid tumors. CNDO-109 has produced impressive results in a Phase I clinical trial in patients with AML and demonstrated preclinical activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer. Coronado plans to file an IND and initiate a Phase I/II dose escalation trial in AML patients in early 2012. 

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.  For more information, please visit

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact Information:

Investor Relations

Noah D. Beerman, Executive Vice President & Chief Operating Officer
Coronado Biosciences, Inc.

Marcy Nanus, Vice President
The Trout Group, LLC.

Media Relations

Dennis S. Dobson Jr., CEO
Dobson Media Group






SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. Coronado Biosciences Reports Third Quarter 2011 Financial Results
7. Coronado Biosciences Commences Public Trading on the OTC Bulletin Board
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Henry Schein ... provider of health care products and services to office-based ... customers that the Henry Schein Disaster Relief Hotline is ... logistical or financial issues as a result of the ... The toll-free number for all Henry Schein ...
(Date:10/9/2015)... Calif. , Oct. 9, 2015  Impax Laboratories, ... Company will release its third quarter 2015 financial results ... of the U.S. financial markets. The Company will host ... community at 8:30 a.m., Eastern Time on November 9, ... . --> The financial results and ...
(Date:10/9/2015)... 2015 Eli Lilly and Company (NYSE: LLY ... approximately 50 new jobs to its research and development presence ... York, New York . --> ... will include a translational immuno-oncology hub and a Lilly "portal," ... access to cutting-edge drug discovery capabilities, including chemistry and lead ...
Breaking Medicine Technology:
...   Ocular Therapeutix, Inc. announced today that it ... Drug Administration to conduct a pivotal clinical trial with ... use over clear corneal incisions. The ... efficacy of the device, relative to sutured closure, for ...
... South Korea, Feb. 6, 2012 /PRNewswire-Asia/ -- As the whole ... in Korea has shown a great improvement. Cancer is still ... half of Korean cancer patients have, in recent times, managed ... world class cancer treatments are available in Korea. ...
Cached Medicine Technology:
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Head ... Center for the elite developmental camp at the Karolyi Ranch in Huntsville, Texas on ... Katreece Stone, Head Over Heels girls team head coach and executive director, said. “It's ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance ... a community improvement initiative that involves working with a series of local charities ... of Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , ...
(Date:10/9/2015)... Nedlands, WA, Australia (PRWEB) , ... October 09, ... ... be featured in an upcoming episode of Innovations with Ed Begley Jr., airing ... In this segment, Innovations will educate audiences on MMJ Phytotech Limited (MMJ) – ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing rainfall has ... Foundation (CCCF) in Columbia, South Carolina. In response, the Foundation has established a ... – both short and long term. 100% of monies donated will go directly ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... medical staffing franchise, was recognized by Cabarrus County Active Living and Parks for ... home care company’s dedication to consistently going above and beyond the ...
Breaking Medicine News(10 mins):
... , , WASHINGTON, July ... for a health reform bill that requires no cost-sharing by ... The preventive services proposal was among eight "core consumer protections" ... He listed the eight protections during a Thursday town hall ...
... percent, chances of serious complications 4.3 percent, , WEDNESDAY, ... surgery to combat significant obesity, a new study suggests ... what has previously been reported. , The study, which ... gastric banding (lap-band surgery), found that the risk of ...
... , ROCKVILLE, Md., ... expect to feel better when taking an antidepressant, which rheumatoid arthritis drugs work ... now can get this and other treatment information through new Spanish-language consumer guides ... AHRQ also released consumer ...
... , ARLINGTON, Va., July 29 ... home medical equipment and services (durable medical equipment) and about ... Association for Homecare has developed a "Myth vs. Reality" list ... The American Association for Homecare urges members of the ...
... study finds no better nutrient value than in conventionally produced ... that beckons from the organic aisles of grocery stores may ... rest of supermarket shelves. , According to a British review ... conventionally produced foods have about the same nutrient content, suggesting ...
... , CHICAGO, July 29 Through its ... and Casualty Company has increased its support to the Alzheimer,s Association ... Bankers, annual Forget Me Not Days(R) event increased its donations ... Alzheimer,s Association. In addition, Bankers - the national life and ...
Cached Medicine News:
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
... Isolated ESU on the market with 10,000V PTP ... that allows the surgeon to adjust power settings ... pencil. Excalibur Plus PC Patented Controlled Output Voltage ... cutting through various impedance tissues with minimal thermal ...
Diamond phaco knife keratome shaped blade straight. 3.2 mm wide....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Medicine Products: